First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

Benzer Materyaller

• First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
  Yazar:: Holleman MS, ve diğerleri
  Baskı/Yayın Bilgisi: (2019-02-01)
• Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
  Yazar:: Holleman, Marscha S., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
  Yazar:: Sullivan, Ivana, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome
  Yazar:: Tiefenbacher, Andreas, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
  Yazar:: Bria, E., ve diğerleri
  Baskı/Yayın Bilgisi: (2011)